Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative studyAgnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genesMarco Mazzotta, Marco Filetti, Mario Occhipinti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung CancerLaura Cipriani, Davide Mascolo, Stefano Scalera, et al.
Cancers|October 14, 2022
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective StudyEriseld Krasniqi, Francesca Sofia Di Lisa, Anna Di Benedetto, et al.
Cancer Biology & Therapy|January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumabLaura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
International Journal of Medical Sciences|April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS TrialEriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
NPJ Breast Cancer|May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo studyEriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Pageof 6